{| class="wikitable" style="text-align:center; width:50%;"
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
|-
| style="background-color:#F0F0F0" |[[File:TravisOsterman.jpg|frameless|upright=0.3|center]]
|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Small cell lung cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''.
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.asco.org/ ASCO]==
*'''2015:''' Rudin et al. [http://ascopubs.org/doi/full/10.1200/JCO.2015.63.7918 Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline] [https://www.ncbi.nlm.nih.gov/pubmed/26351333 PubMed]
==[http://www.esmo.org/ ESMO]==
*'''2013:''' Fr√ºh et al. [https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Small-Cell-Lung-Cancer Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/23813929 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf NCCN Guidelines - Small Cell Lung Cancer]

=Limited stage, induction=
==Carboplatin & Etoposide {{#subobject:f0013f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''toposide, '''<u>P</u>'''araplatin (Carboplatin)
===Variant #1, 2 days of oral etoposide per cycle {{#subobject:89f0ef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 Lee et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Thalidomide, then RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once on day 1, then 100 mg PO twice per day on days 2 & 3

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Patients with complete or partial responses: [[#Radiation_therapy|Thoracic radiotherapy]] and [[#Whole_brain_irradiation|prophylactic cranial irradiation]], approximately 3 weeks after the last cycle, "according to local practice".

===Variant #2, 1 day of oral etoposide per cycle {{#subobject:3cbc9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 Lee et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Thalidomide, then RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 100 mg PO twice per day on day 3

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Patients with complete or partial responses: [[#Radiation_therapy|Thoracic radiotherapy]] and [[#Whole_brain_irradiation|prophylactic cranial irradiation]], approximately 3 weeks after the last cycle, "according to local practice".

===References===
# Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57. Epub 2009 Jul 16. [https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19608997 PubMed]

==Cisplatin & Etoposide {{#subobject:189bcc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:dd9b40|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/3/11/1471.long Evans et al. 1985]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients with limited stage disease responding to therapy received [[#Whole_brain_irradiation|prophylactic cranial irradiation]], 4 Gy fractions given once per day x 5 fractions (total dose: 20 Gy) over 5 days between cycles 3 and 4.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV slow push once per day on days 1 to 3, '''given second'''
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over at least 30 minutes once per day on days 1 to 3, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV once prior to chemotherapy
*[[Metoclopramide (Reglan)]] 10 mg IV or PO once prior to chemotherapy
*[[Prochlorperazine (Compazine)]] 10 mg PO/IM once prior to chemotherapy
*"No special efforts were made to hydrate the patients," though PO fluid intake was encouraged, and 500 mL normal saline was given with etoposide infusion.

'''21 to 28-day cycle for 6 cycles'''

====Subsequent treatment====
*[[#Radiation_therapy|Thoracic radiation]]
===References===
# Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed]

=Limited stage, definitive chemoradiotherapy=
==Carboplatin, Etoposide, RT {{#subobject:6c0ece|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP & RT: '''<u>E</u>'''toposide, '''<u>P</u>'''araplatin (Carboplatin), '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1 {{#subobject:9e4385|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/12/9/1231.long Skarlos et al. 2001]
| style="background-color:#1a9851" |Randomized Phase II (E)
|Carboplatin, Etoposide, early HTRT
| style="background-color:#d9ef8b" |Might have superior ORR
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 60 minutes once on day 1, '''given first, before etoposide'''
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, '''given second, after carboplatin'''
*Concurrent [[External beam radiotherapy|hyperfractionated thoracic radiation therapy (HTRT)]], 1.5 Gy fractions given twice per day (at least 4, but preferably 6 hours between fractions) x 30 fractions (total dose: 45 Gy) over 3 weeks. Skarlos et al. 2001 examined two different timings for radiation therapy. There was no significant difference between early vs. late HTRT, though there was a trend toward higher response rate for late HTRT. Early HTRT is given during cycle 1 of chemotherapy; late HTRT is given during cycle 4 of chemotherapy.

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Patients with CR: [[#Whole_brain_irradiation|Prophylactic cranial irradiation]]

===Variant #2 {{#subobject:bb6fc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/17/11/3540.long Okamoto et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients in Okamoto et al. 1999 were greater than or equal to 70 years old.''
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1, '''given first'''
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3, '''given second'''
*[[External beam radiotherapy|Thoracic radiation]], '''given third'''
*Palliative radiation therapy was allowed to control persistent pain from bony metastases

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1 to 3 prior to chemotherapy
*[[Granisetron]] 40 mcg/kg IV once per day on days 1 to 3 prior to chemotherapy
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] 2 mcg/kg SC given for grade 3 or greater leukopenia/neutropenia

'''28-day cycle for up to 4 cycles'''

===References===
<!-- Presented in part at the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998. -->
# Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. [http://jco.ascopubs.org/content/17/11/3540.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10550152 PubMed]
# Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. [http://annonc.oxfordjournals.org/content/12/9/1231.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11697833 PubMed]

==Cisplatin, Etoposide, RT {{#subobject:fb5cd7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP & RT: '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), '''<u>R</u>'''adiation '''<u>T</u>'''herapy
<br>PE + RT: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''toposide, '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 60/360/45 {{#subobject:63584c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199901283400403 Turrisi et al. 1999 (Intergroup 0096)]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, once per day RT
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.50 Gy fractions given twice per day x 30 fractions over 3 weeks, given during cycle 1 of chemotherapy (total dose: 45 Gy)

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*After completing 4 cycles of chemotherapy, patients were restaged. Because of the high rate of brain metastases (50%), patients with CR were offered [[#Whole_brain_irradiation|Prophylactic cranial irradiation]]

===Variant #2, 70/300/52.5, early RT {{#subobject:97533b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/annonc/article/24/8/2088/196699 Sun et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|EP & late RT
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#fc8d59" |Seems to have higher rates of neutropenic fever
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.10 Gy fractions x 25 fractions over 5 weeks, given during cycle 1 of chemotherapy (total dose: 52.5 Gy)

'''21-day cycle for 4 cycles'''

===Variant #3, 70/300/52.5, late RT {{#subobject:2140dc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/annonc/article/24/8/2088/196699 Sun et al. 2013]
| style="background-color:#1a9851" |Phase III (E)
|EP & early RT
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#91cf60" |Seems to have lower rates of neutropenic fever
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.10 Gy fractions x 25 fractions over 5 weeks, given during cycle 3 of chemotherapy (total dose: 52.5 Gy)

'''21-day cycle for 4 cycles'''

===Variant #4, 75/180/45, pre-planned dose reduction {{#subobject:2b9803|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.7.1632 Bunn et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Etoposide, RT, GM-CSF
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |Inferior hematologic toxicity
|-
|}
''Note: toxicity was the primary endpoint in this study.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] as follows:
**Cycles 1 to 3: 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
**Cycles 4 to 6: 40 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] as follows:
**Cycles 1 to 3: 60 mg/m<sup>2</sup> IV once per day on days 1 to 3
**Cycles 4 to 6: 50 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]] during cycles 1 & 2, 1.80 Gy fractions x 25 fractions (total dose: 45 Gy)

'''21-day cycle for 6 cycles'''

===Variant #5, 75/300/45 {{#subobject:7ed43e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437/ Faivre-Finn et al. 2017 (CONVERT)]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, once per day RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.50 Gy fractions given twice per day x 30 fractions over 3 weeks, given during cycle 1 of chemotherapy (total dose: 45 Gy)

'''21-day cycle for 4 or 6 cycles'''

===Variant #6, 75/300/45, split doses of cisplatin {{#subobject:c54e7b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437/ Faivre-Finn et al. 2017 (CONVERT)]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, once per day RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.50 Gy fractions given twice per day x 30 fractions over 3 weeks, given during cycle 1 of chemotherapy (total dose: 45 Gy)

'''21-day cycle for 4 or 6 cycles'''

===Variant #7, 75/700/42, partially oral etoposide {{#subobject:b5305|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/24/4665.long Sundstr√∏m et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|[[Small_cell_lung_cancer_-_historical#CEV_.26_RT|CEV & RT]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once on day 1; then 200 mg/m<sup>2</sup> PO once per day on days 2 to 4, taken on an empty stomach
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]], 2.8 Gy fractions given once per day x 15 fractions (total dose: 42 Gy) over 3 weeks, given "between the third and fourth chemotherapy courses"

====Supportive medications====
*"Standard prehydration and posthydration procedures were followed in conjunction with cisplatin administration."

'''21-day cycle for up to 5 cycles'''
====Subsequent treatment====
*Patients with CR: [[#Whole_brain_irradiation|Prophylactic cranial irradiation]]

===Variant #8, 80/240/50 {{#subobject:d203ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://insights.ovid.com/pubmed?pmid=15685040 McClay et al. 2005 (CALGB 9235)]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, Tamoxifen, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]], 200 cGy fractions given once per day x 25 fractions (total dose: 50 Gy) over 5 weeks, started on cycle 4 day 1 of chemotherapy

'''21-day cycle for 5 cycles'''

===Variant #9, 80/300/45, 1 cycle of chemo {{#subobject:6426d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/33/5247.full Saito et al. 2006 (WJTOG 9902)]
| style="background-color:#91cf61" |Phase II
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470204513705114/fulltext Kubota et al. 2013 (JCOG0202)]
|Non-randomized portion of RCT
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]], 1.5 Gy fractions given twice per day (at least 4, but preferably 6 hours between fractions) x 30 fractions (total dose: 45 Gy) over 3 weeks, started on cycle 1 day 2 of chemotherapy

'''28-day cycle for 1 cycle'''
====Subsequent treatment====
*WJTOG 9902: [[#Cisplatin_.26_Irinotecan|IP consolidation]]
*JCOG0202: EP x 3 versus [[#Cisplatin_.26_Irinotecan|IP]] consolidation

===Variant #10, 80/300/45, 4 cycles of chemo {{#subobject:77843f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/14/3054.long Takada et al. 2002 (JCOG 9104)]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, sequential RT
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]], 1.5 Gy fractions given twice per day (4 or more hours between fractions) x 30 fractions (total dose: 45 Gy) over 3 weeks, started on cycle 1 day 2 of chemotherapy

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*JCOG 9104 patients with CR or near-CR ("a scar-like shadow on chest films but no positive cytology and/or bronchoscopic biopsy"): [[#Whole_brain_irradiation|Prophylactic cranial irradiation]]

===Variant #11, 90/300/39.9 {{#subobject:71c93e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/19/10/1691/240182 Sculier et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|Cisplatin, Etoposide, RT (daily cisplatin)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 90 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.66 Gy fractions given once per day x 15 fractions over 3 weeks, given during cycle 1 of chemotherapy (total dose: 39.9 Gy)

'''21-day cycle for up to 6 cycles'''
===References===
# Bunn PA Jr, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul;13(7):1632-41. Erratum in: J Clin Oncol 1995 Nov;13(11):2860. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.7.1632 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7602352 PubMed]
# '''Intergroup 0096:''' Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71. [https://www.nejm.org/doi/full/10.1056/NEJM199901283400403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9920950 PubMed]
# '''JCOG 9104:''' Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60. [http://jco.ascopubs.org/content/20/14/3054.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12118018 PubMed] content property of [http://hemonc.org HemOnc.org]
# Sundstr√∏m S, Bremnes RM, Kaasa S, Aaseb√∏ U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. [http://jco.ascopubs.org/content/20/24/4665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488411 PubMed]
# '''CALGB 9235:''' McClay EF, Bogart J, Herndon JE 2nd, Watson D, Evans L, Seagren SL, Green MR; Cancer and Leukemia Group B Study (9235). A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol. 2005 Feb;28(1):81-90. [https://insights.ovid.com/pubmed?pmid=15685040 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15685040 PubMed]
# Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed]
# Sculier JP, Lafitte JJ, Efremidis A, Florin MC, Lecomte J, Berchier MC, Richez M, Berghmans T, Scherpereel A, Meert AP, Koumakis G, Leclercq N, Paesmans M, Van Houtte P; European Lung Cancer Working Party (ELCWP). A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol. 2008 Oct;19(10):1691-7. Epub 2008 May 25. [https://academic.oup.com/annonc/article/19/10/1691/240182 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18504252 PubMed]
# Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013 Aug;24(8):2088-92. Epub 2013 Apr 16. Erratum in: Ann Oncol. 2014 Aug;25(8):1672. [https://academic.oup.com/annonc/article/24/8/2088/196699 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23592701 PubMed]
# '''JCOG0202:''' Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014 Jan;15(1):106-13. Epub 2013 Dec 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470204513705114/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24309370 PubMed]
# '''CONVERT:''' Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125. Epub 2017 Jun 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470204517303182/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28642008 PubMed]

=Limited state, consolidation after upfront therapy=
==Cisplatin & Irinotecan {{#subobject:fe9413|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IP: '''<u>I</u>'''rinotecan, '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:540b9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/33/5247.full Saito et al. 2006 (WJTOG 9902)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Etoposide.2C_RT|Cisplatin, Etoposide, RT induction]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] (no additional details given) starting after day 4

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*Patients with complete or good partial responses: [[#Whole_brain_irradiation|Prophylactic cranial irradiation]]

===References===
# '''WJTOG 9902:''' Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.12.2924 Kelly et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|IFN alfa-2a
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment.''
====Preceding treatment====
*Chemoradiotherapy
===References===
# Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, Livingston R. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec;13(12):2924-30. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.12.2924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8523056 PubMed]

==Radiation therapy {{#subobject:508a85|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c48aca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/3/11/1471.long Evans et al. 1985]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#Cisplatin_.26_Etoposide|EP]] x 6
====Radiotherapy====
*"Patients who did not have evidence of tumor spread beyond the mediastinum and/or ipsilateral supraclavicular notes" received [[External beam radiotherapy|thoracic radiation]] in 250 cGy fractions x 10 fractions (total dose: 25 Gy)
===References===
# Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed]
# Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57. Epub 2009 Jul 16. [https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19608997 PubMed]

==Whole brain irradiation {{#subobject:49c1e3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCI: '''<u>P</u>'''rophylactic '''<u>C</u>'''ranial '''<u>I</u>'''rradiation
===Variant #1, 20 Gy {{#subobject:900486|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/373562 Cox et al. 1981]
| style="background-color:#91cf61" |Non-randomized
|-
|[http://jco.ascopubs.org/content/3/11/1471.long Evans et al. 1985]
| style="background-color:#91cf61" |Phase II
|-
|[http://annonc.oxfordjournals.org/content/12/9/1231.long Skarlos et al. 2001]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: in Evans et al. 1985, the WB-XRT is given in-between cycles 3 & 4.''
====Preceding treatment====
*Evans et al. 1985: [[#Cisplatin_.26_Etoposide|EP]] x 3
*Skarlos et al. 2001: [[#Carboplatin.2C_Etoposide.2C_RT|EP & early HTRT]] versus [[#Carboplatin.2C_Etoposide.2C_RT|EP & late HTRT]]
====Radiotherapy====
*[[External beam radiotherapy|Whole brain irradiation]], 4 Gy fractions given once per day x 5 fractions (total dose: 20 Gy)
====Subsequent treatment====
*Evans et al. 1985: [[#Cisplatin_.26_Etoposide|EP]] x 3

===Variant #2, 24 Gy {{#subobject:5b88f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/14/3054.long Takada et al. 2002 (JCOG 9104)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Etoposide.2C_RT|EP & RT]] versus EP, then RT
====Prophylactic whole-brain irradiation====
*[[External beam radiotherapy|Whole brain irradiation]], 1.5 Gy fractions given twice per day, 5 days per week, x 16 fractions (total dose: 24 Gy)

===Variant #3, 25 Gy {{#subobject:1475db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199901283400403 Turrisi et al. 1999 (Intergroup 0096)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/24/33/5247.full Saito et al. 2006 (WJTOG 9902)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70101-9/fulltext Le P√©choux et al. 2009 (PCI 99-01/EORTC 22003-08004/RTOG 0212/IFCT 99-01)]
| style="background-color:#1a9851" |Phase III (C)
|PCI x 36 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*Intergroup 0096: [[#Cisplatin.2C_Etoposide.2C_RT|EP & once-daily RT]] versus [[#Cisplatin.2C_Etoposide.2C_RT|EP & twice-daily RT]]
*WJTOG 9902: [[#Cisplatin.2C_Etoposide.2C_RT|EP & RT]], then [[#Cisplatin_.26_Irinotecan|IP]] x 3
====Radiotherapy====
*[[External beam radiotherapy|Whole brain irradiation]], 2.5 Gy fractions x 10 fractions (total dose: 25 Gy)

===Variant #4, 30 Gy {{#subobject:63970e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/20/24/4665.long Sundstr√∏m et al. 2002]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[Small_cell_lung_cancer_-_historical#CEV_.26_RT|CEV & RT]] versus [[#Cisplatin.2C_Etoposide.2C_RT|EP & RT]]
====Radiotherapy====
*[[External beam radiotherapy|Whole brain irradiation]], 2 Gy fractions given once per day x 15 fractions (total dose: 30 Gy)

===References===
# Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R. Cranial irradiation in cancer of the lung of all cell types. JAMA. 1981 Feb 6;245(5):469-72. [https://jamanetwork.com/journals/jama/fullarticle/373562 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7452872 PubMed]
# Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed]
# '''Intergroup 0096:''' Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71. [https://www.nejm.org/doi/full/10.1056/NEJM199901283400403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9920950 PubMed]
# '''Meta-analysis:''' Aup√©rin A, Arriagada R, Pignon JP, Le P√©choux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999 Aug 12;341(7):476-84. [https://www.nejm.org/doi/10.1056/NEJM199908123410703 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10441603 PubMed]
# '''JCOG 9104:''' Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60. [http://jco.ascopubs.org/content/20/14/3054.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12118018 PubMed] content property of [http://hemonc.org HemOnc.org]
# Sundstr√∏m S, Bremnes RM, Kaasa S, Aaseb√∏ U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. [http://jco.ascopubs.org/content/20/24/4665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488411 PubMed]
# '''WJTOG 9902:''' Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006 Nov 20;24(33):5247-52. [http://jco.ascopubs.org/content/24/33/5247.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17114657 PubMed]
# '''PCI 99-01/EORTC 22003-08004/RTOG 0212/IFCT 99-01:''' Le P√©choux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. Epub 2009 Apr 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70101-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19386548 PubMed]

=Extensive stage, induction=

==Belotecan & Cisplatin {{#subobject:9fbf31|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BP: '''<u>B</u>'''elotecan and '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:949381|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/ Oh et al. 2016 (COMBAT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|EP 60/100]]
| style="background-color:#eeee01" |Non-inferior RR
|-
|}
''Note: the total number of planned cycles is not described in the manuscript; total duration information here was provided by the authors.''
====Chemotherapy====
*[[Belotecan (Camptobell)]] 0.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 4
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 to 8 cycles'''

===References===
# '''COMBAT:''' Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. BMC Cancer. 2016 Aug 26;16:690. [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2741-z link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27566413 PubMed]

==Carboplatin & Etoposide {{#subobject:de3ba6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC: '''<u>E</u>'''toposide & '''<u>C</u>'''arboplatin
<br>EP: '''<u>E</u>'''toposide & '''<u>P</u>'''araplatin (Carboplatin)
<br>CE: '''<u>C</u>'''arboplatin & '''<u>E</u>'''toposide
<br>Ca/E: '''<u>Ca</u>'''rboplatin & '''<u>E</u>'''toposide
===Variant #1, AUC 4/600, PO etoposide {{#subobject:8ac097|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.15.7545 Hermes et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#Carboplatin_.26_Irinotecan|IC]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 (Chatelut formula) IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 4 cycles'''

===Variant #2, AUC 5/240 {{#subobject:471848|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ Okamoto et al. 2007 (JCOG 9702)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|Split-dose PE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(13)00232-5/fulltext Sekine et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|Amrubicin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*JCOG 9702: [[:Category:Granulocyte colony-stimulating factors|G-CSF]]

'''21-day cycle for 4 to 6 cycles'''

===Variant #3, AUC 5/300 {{#subobject:1eba05|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/28/4787.long Socinski et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin & Pemetrexed
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 Spigel et al. 2011 (SALUTE)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Carboplatin.2C_Etoposide.2C_Bevacizumab|Carboplatin, Etoposide, Bevacizumab]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ Ready et al. 2015 (CALGB 30504)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.67.6601 Reck et al. 2016 (CA184-156)]
|style="background-color:#1a9851" |Phase III (C)
|CE & Ipilimumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7454 Jalal et al. 2017 (MATISSE)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|PaCE
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 Horn et al. 2018 (IMpower133)]
|style="background-color:#1a9851" |Phase III (C)
|[[#Carboplatin.2C_Etoposide.2C_Atezolizumab|CE & Atezolizumab]], then [[#Atezolizumab_maintenance|Atezolizumab maint.]]
| style="background-color:#d73027" |Inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*Socinksi et al. 2009: "supportive therapies, such as erythropoietic agents or granulocyte colony-stimulating factors, were administered according to the American Society of Clinical Oncology guidelines"

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*CALGB 30504, SD or better: [[#Observation_2|Observation]] versus [[#Sunitinib_monotherapy|sunitinib maintenance]]

===Variant #4, AUC 5 or 6/360 {{#subobject:927150|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 or 6 (maximum dose of 1000 mg) IV once on day 1 
**AUC 5 is used if eGFR calculated by EDTA; AUC 6 is used if eGFR calculated by Cockcroft Gault. If eGFR greater than 130 mL/min/1.73m<sup>2</sup>, dose calculation to be capped at GFR = 130 mL/min/1.73m<sup>2</sup>
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for 6 cycles'''

===Variant #5, AUC 5/420 {{#subobject:69fffb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/17/4/663.long Schmittel et al. 2006]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Carboplatin_.26_Irinotecan|IP]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1 
*[[Etoposide (Vepesid)]] 140 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 3

====Supportive medications====
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV before chemotherapy
*[[Loperamide (Imodium)]] 4 mg PO prn first episode of diarrhea, then loperamide 2 mg PO Q2H until diarrhea stops

'''21-day cycle for up to 6 cycles'''

===Variant #6, AUC 5 or 6/440, 1 day of oral etoposide per cycle {{#subobject:47c27e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 Lee et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Thalidomide 
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 or 6 (maximum dose of 1000 mg) IV once on day 1
**'''Lee et al. 2009''': AUC 5 is used
**'''LUNGSTAR''': AUC 5 is used if eGFR calculated by EDTA; AUC 6 is used if eGFR calculated by Cockcroft Gault. If eGFR greater than 130 mL/min/1.73m<sup>2</sup>, dose calculation to be capped at GFR = mL/min/1.73m<sup>2</sup>
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 100 mg PO twice per day on day 3

'''21-day cycle for up to 6 cycles'''

===Variant #7, AUC 5 or 6/520, 2 days of oral etoposide per cycle {{#subobject:ae04e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 Lee et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Thalidomide
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 or 6 (maximum dose of 1000 mg) IV once on day 1
**'''Lee et al. 2009''': AUC 5 is used
**'''LUNGSTAR''': AUC 5 is used if eGFR calculated by EDTA; AUC 6 is used if eGFR calculated by Cockcroft Gault. If eGFR greater than 130 mL/min/1.73m<sup>2</sup>, dose calculation to be capped at GFR = mL/min/1.73m<sup>2</sup>
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once on day 1, then 100 mg PO twice per day on days 2 & 3

'''21-day cycle for up to 6 cycles'''

===Variant #8, AUC 5/300, 28-day cycles {{#subobject:d904aa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/17/11/3540.long Okamoto et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|[http://annonc.oxfordjournals.org/content/12/7/957.long Quoix et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|}
''Patients in Okamoto et al. 1999 and Quoix et al. 2001 were greater than or equal to 70 years old.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1, '''given first'''
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3, '''given second'''
*Palliative radiation therapy was allowed to control persistent pain from bony metastases

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg IV once on days 1 to 3 prior to chemotherapy
*[[Granisetron]] 40 mcg/kg IV once on days 1 to 3 prior to chemotherapy
*Okamoto et al. 1999: [[:Category:Granulocyte colony-stimulating factors|G-CSF]] 2 mcg/kg SC given for grade 3 or greater leukopenia/neutropenia
*Quiox et al. 2001: "Haematopoietic growth factors were allowed as prophylactic or curative treatment only if grade 4 neutropenia greater than 7 days occurred"

'''28-day cycle for 4 to 6 cycles'''

===References===
# Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. [http://jco.ascopubs.org/content/17/11/3540.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10550152 PubMed]
# Quoix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, Kessler R, Moreau L, Co√´tmeur D, Lemari√© E, Milleron B. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol. 2001 Jul;12(7):957-62. [http://annonc.oxfordjournals.org/content/12/7/957.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11521802 PubMed]
# Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):663-7. Epub 2006 Jan 19. [http://annonc.oxfordjournals.org/content/17/4/663.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16423848 PubMed]
## '''Update:''' Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25. [http://annonc.oxfordjournals.org/content/22/8/1798.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21266516 PubMed]
# '''JCOG 9702:''' Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007 Jul 16;97(2):162-9. Epub 2007 Jun 19. [https://www.nature.com/articles/6603810 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17579629 PubMed]
# Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstr√∏m S, Thaning L, Vilsvik J, Aaseb√∏ U, S√∂renson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.7545 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18779613 PubMed]
# Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57. Epub 2009 Jul 16. [https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp200 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19608997 PubMed]
<!-- Presented in part as an oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL, and the 8th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting, February 20-23, 2008, Santa Monica, CA. -->
# Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009 Oct 1;27(28):4787-92. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4787.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19720897 PubMed]
# '''SALUTE:''' Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21502556 PubMed]
# Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M. A randomized phase III study of single-agent amrubicin vs carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. Clin Lung Cancer. 2014 Mar;15(2):96-102. Epub 2013 Nov 14. [https://www.clinical-lung-cancer.com/article/S1525-7304(13)00232-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24361248 PubMed]
# '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed]
# '''CA184-156:''' Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016 Nov 1;34(31):3740-3748. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.6601 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27458307 PubMed]
# '''LUNGSTAR:''' Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017 May 10;35(14):1506-1514. Epub 2017 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.7391 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28240967 PubMed]
# '''MATISSE:''' Jalal SI, Lavin P, Lo G, Lebel F, Einhorn L. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: A multicenter, adaptive, randomized phase III study (MATISSE). J Clin Oncol. 2017 Aug 10;35(23):2619-2623. Epub 2017 Jun 12. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.7454 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28605291 PubMed]
# '''IMpower133:''' Horn L, Mansfield AS, Szczƒôsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Sep 25. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280641 PubMed]

==Carboplatin, Etoposide, Atezolizumab {{#subobject:760b97|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6a356b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 Horn et al. 2018 (IMpower133)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#IMpower133|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#IMpower133|See link]]
|-
|}
====Chemoimmunotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Atezolizumab_maintenance|Atezolizumab maintenance]]

===References===
# '''IMpower133:''' Horn L, Mansfield AS, Szczƒôsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Sep 25. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280641 PubMed]

==Carboplatin, Etoposide, Bevacizumab {{#subobject:d61f26|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3eed0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 Spigel et al. 2011 (SALUTE)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===References===
# Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21502556 PubMed]

==Carboplatin & Irinotecan {{#subobject:b2ac71|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IC: '''<u>I</u>'''rinotecan & '''<u>C</u>'''arboplatin
<br>IP: '''<u>I</u>'''rinotecan & '''<u>P</u>'''araplatin (Carboplatin)
===Variant #1, AUC 4/175 {{#subobject:3de550|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.15.7545 Hermes et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[#Carboplatin_.26_Etoposide_2|EC]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 (Chatelut formula) IV once on day 1
*[[Irinotecan (Camptosar)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #2, AUC 5/150 {{#subobject:38a7ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/17/4/663.long Schmittel et al. 2006]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Carboplatin_.26_Etoposide_2|EP]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1 
*[[Irinotecan (Camptosar)]] 50 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

====Supportive medications====
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV before chemotherapy
*[[Loperamide (Imodium)]] 4 mg PO prn first episode of diarrhea, then 2 mg PO Q2H until diarrhea stops

'''28-day cycle for up to 6 cycles'''

===References===
# Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):663-7. Epub 2006 Jan 19. [http://annonc.oxfordjournals.org/content/17/4/663.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16423848 PubMed]
## '''Update:''' Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25. [http://annonc.oxfordjournals.org/content/22/8/1798.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21266516 PubMed]
# Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstr√∏m S, Thaning L, Vilsvik J, Aaseb√∏ U, S√∂renson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.7545 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18779613 PubMed]

==Carboplatin, Paclitaxel, Ipilimumab {{#subobject:9695b3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, phased ipilimumab {{#subobject:7dbd39|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://annonc.oxfordjournals.org/content/24/1/75.long Reck et al. 2011]
| rowspan="2" style="background-color:#1a9851" |Randomized Phase II (E)
|1. Carboplatin & Paclitaxel
| style="background-color:#91cf60" |Seems to have superior irPFS
|-
|2. Carboplatin, Paclitaxel, concurrent Ipilimumab
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemoimmunotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Ipilimumab (Yervoy)]] as follows:
**Cycles 1 & 2: no treatment
**Cycles 3 to 6: 10 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles''' 
====Subsequent treatment====
*[[#Ipilimumab_monotherapy|Ipilimumab maintenance]]

===Variant #2, concurrent ipilimumab {{#subobject:069d62|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://annonc.oxfordjournals.org/content/24/1/75.long Reck et al. 2011]
| rowspan="2" style="background-color:#1a9851" |Randomized Phase II (E)
|1. Carboplatin & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Carboplatin, Paclitaxel, phased Ipilimumab
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemoimmunotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Ipilimumab (Yervoy)]] as follows:
**Cycles 1 to 4: 10 mg/kg IV once on day 1
**Cycles 5 & 6: no treatment

'''21-day cycle for up to 6 cycles''' 
====Subsequent treatment====
*[[#Ipilimumab_monotherapy|Ipilimumab maintenance]]

===References===
# Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. [http://annonc.oxfordjournals.org/content/24/1/75.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22858559 PubMed]

==Cisplatin & Etoposide {{#subobject:ec90cd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''toposide and '''<u>P</u>'''latinol (Cisplatin)
<br>PE: '''<u>P</u>'''latinol (Cisplatin) and '''<u>E</u>'''toposide
===Variant #1, 60/300 {{#subobject:dd1718|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/ Oh et al. 2016 (COMBAT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Belotecan_.26_Cisplatin|BP]]
| style="background-color:#eeee01" |Non-inferior RR
|-
|}
''Note: the total number of planned cycles is not described in the manuscript; total duration information here was provided by the authors.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for 4 to 8 cycles'''

===Variant #2, 60/360 {{#subobject:5c4b41|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/13/2038.long Hanna et al. 2006]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Irinotecan_2|Cisplatin & Irinotecan]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*Per Hanna et al. 2006:
**[[:Category:Granulocyte colony-stimulating factors|G-CSF]] used according to 1999 American Society of Clinical Oncology guidelines
**"Erythropoietin was allowed at the discretion of the treating physician."

'''21-day cycle for 4 to 6 cycles'''

===Variant #3, 60/440, 1 day of oral etoposide per cycle {{#subobject:47c27e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 100 mg PO twice per day on day 3

'''21-day cycle for up to 6 cycles'''

===Variant #4, 60/520, 2 days of oral etoposide per cycle {{#subobject:ae04e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ Seckl et al. 2017 (LUNGSTAR)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, Etoposide, Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once on day 1, then 100 mg PO twice per day on days 2 & 3

'''21-day cycle for up to 6 cycles'''

===Variant #5, 75/240, split cisplatin {{#subobject:8907be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ Okamoto et al. 2007 (JCOG 9702)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Carboplatin_.26_Etoposide_2|CE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21- to 28-day cycle for 4 cycles'''

===Variant #6, 75/300 {{#subobject:da2da4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)70409-0/pdf Ignatiadis et al. 2005]
|style="background-color:#1a9851" |Phase III (C)
|PE/Topotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 Spigel et al. 2011 (SALUTE)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Cisplatin.2C_Etoposide.2C_Bevacizumab|Cisplatin, Etoposide, Bevacizumab]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|rowspan=2|[https://www.jto.org/article/S1556-0864(15)32944-0/fulltext Fink et al. 2012]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. Cisplatin & Topotecan
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. Etoposide & Topotecan
| style="background-color:#d3d3d3" |Not reported
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.67.6601 Reck et al. 2016 (CA184-156)]
|style="background-color:#1a9851" |Phase III (C)
|PE & Ipilimumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for 4 (SALUTE) or 6 (Fink et al. 2012 & CA184-156) cycles'''

===Variant #7, 75/300, split cisplatin {{#subobject:a51a22|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/3/11/1471.long Evans et al. 1985]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.69.4844 Tiseo et al. 2017 (GOIRC-AIFA FARM6PMFJM)]
| style="background-color:#1a9851" |Phase III (C)
|PE & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: in Evans et al. 1985, patients with disease responding to therapy received prophylactic cranial irradiation, 4 Gy fractions given daily x 5 fractions (total dose: 20 Gy) over 5 days between cycles 3 and 4; Locoregional radiation therapy was only used if symptoms persisted after 6 cycles of treatment: Radiation therapy, 250 cGy/rad fractions x 10 fractions (total dose: 2500 cGy/rad), given after cycle 6 of chemotherapy.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV slow push once per day on days 1 to 3, '''given second'''
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over at least 30 minutes once per day on days 1 to 3, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV once prior to chemotherapy
*[[Metoclopramide (Reglan)]] 10 mg IV or PO once prior to chemotherapy
*[[Prochlorperazine (Compazine)]] 10 mg PO/IM once prior to chemotherapy
*"No special efforts were made to hydrate the patients," though PO fluid intake was encouraged, and 500 mL normal saline was given with etoposide infusion.

'''21- to 28-day cycle for up to 6 cycles'''

===Variant #8, 75/390, split cisplatin {{#subobject:3ed519|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.8.1871 Miller et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Oral Etoposide
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Etoposide (Vepesid)]] 130 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for 8 cycles'''

===Variant #9, 75/700, 3 days of oral etoposide per cycle {{#subobject:807314|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/24/4665.long Sundstr√∏m et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|[[Small_cell_lung_cancer_-_historical#CEV|CEV]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Patients in Sundstr√∏m et al. 2002 with extensive stage disease did not routinely receive radiation therapy. "However, chest or cranial irradiation was optional if severe symptoms could not be palliated by chemotherapy."''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once on day 1, then 200 mg/m<sup>2</sup> PO once per day on days 2 to 4, taken on an empty stomach

====Supportive medications====
*"Standard prehydration and posthydration procedures were followed in conjunction with cisplatin administration."

'''21-day cycle for up to 5 cycles'''

===Variant #10, 80/240 {{#subobject:7b3c2e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/12/10/2022.long Ihde et al. 1994]
| style="background-color:#1a9851" |Phase III (C)
|High-dose EP
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.09.071 Niell et al. 2005 (CALGB 9732)]
| style="background-color:#1a9851" |Phase III (C)
|PET
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 3
*Concurrent [[External_beam_radiotherapy|radiation therapy]] with the start of chemotherapy was given to patients with brain metastases, epidural metastases, and impending pathologic bone fractures
*Patients with carcinomatous meningitis received [[Methotrexate (MTX)]] IT (dose/schedule not specified) and radiation to functionally compromised areas of the CNS

====Supportive medications====
*"Half-normal saline was infused for 2 to 6 hours with [[Cisplatin (Platinol)]], usually in conjunction with a diuretic."
*Corticosteroids were usually given for patients receiving radiation therapy for brain and epidural metastases.

'''21-day cycle for 4 to 8 cycles'''
====Subsequent treatment====
*Ihde et al. 1994, CR after 4 cycles: an additional 4 cycles. Some patients were randomized to receive prophylactic cranial irradiation. Radiation could also be given at the patient's request. No details about dose/schedule given.
*Ihde et al. 1994, PR, no response, or progressive disease: [[Small_cell_lung_cancer_-_historical#CAV_3|Salvage CAV]] or "an individualized 3-drug in vitro-selected regimen (IVSR) during cycles 5 to 8 if drug-sensitivity testing data were available."

===Variant #11, 80/300 {{#subobject:26b7f1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://academic.oup.com/jnci/article-abstract/83/12/855/956642 Fukuoka et al. 1991 (JCOG8502)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[Small_cell_lung_cancer_-_historical#CAV.2FPE|CAV/PE]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://www.karger.com/Article/Abstract/227087 Miyamoto et al. 1992]
| style="background-color:#1a9851" |Phase III (C)
|PEI
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa003034 Noda et al. 2002 (JCOG 9511)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Irinotecan_2|IP]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.3332 Eckardt et al. 2006]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Topotecan
| style="background-color:#eeee01" |Non-inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684855/ Lara et al. 2009 (SWOG S0124)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Irinotecan_2|IP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/21/9/1810/145843 Zatloukal et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Irinotecan_2|IP]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|[http://ar.iiarjournals.org/content/30/7/3031.long Baka et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|PE/T
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ Ready et al. 2015 (CALGB 30504)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826513/ Sun et al. 2016]
| style="background-color:#1a9851" |Phase III (C)
|Amrubicin & Cisplatin
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
**JCOG8502 & Miyamoto et al. 1992 gave etoposide on days 1, 3, 5
====Supportive medications====
*"Hydration and administration of antiemetic drugs."

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*Baka et al. 2010: Topotecan x 4
*CALGB 30504, SD or better: [[#Observation_2|Observation]] versus [[#Sunitinib_monotherapy|sunitinib maintenance]]

===Variant #12, 80/400, split cisplatin {{#subobject:d389d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1995.13.10.2594 Loehrer et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|[[Small_cell_lung_cancer_-_historical#VIP|VIP]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 4

'''21-day cycle for 4 cycles'''

===Variant #13, 80/600, 2 days of oral etoposide per cycle {{#subobject:998892|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527803/ Baka et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[Small_cell_lung_cancer_-_historical#ACE|ACE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once on day 1, then 240 mg/m<sup>2</sup>/day PO on days 2 & 3

'''21-day cycle for 6 cycles'''

===Variant #14, 100/300 {{#subobject:5b54c7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/93/4/300/2906465 Pujol et al. 1991]
| style="background-color:#1a9851" |Phase III (C)
|[[Small_cell_lung_cancer_-_historical#PCDE|PCDE]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.clinical-lung-cancer.com/article/S1525-7304(11)70217-0/pdf Artal-Cort√©s et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Epirubicin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 2
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for 6 cycles'''

===Variant #15, 100/400, split cisplatin {{#subobject:f8e87a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.1992.10.2.282 Roth et al. 1992]
| style="background-color:#1a9851" |Phase III (C)
|1. [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]]<br> 2. [[Small_cell_lung_cancer_-_historical#CAV.2FPE|CAV/PE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Etoposide (Vepesid)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''21-day cycle for 4 cycles'''

===References===
# Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985 Nov;3(11):1471-7. [http://jco.ascopubs.org/content/3/11/1471.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2997406 PubMed]
# '''JCOG8502:''' Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855-61. [https://academic.oup.com/jnci/article-abstract/83/12/855/956642 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1648142 PubMed]
# Miyamoto H, Nakabayashi T, Isobe H, Akita H, Kawakami Y, Arimoto T, Asakawa M, Suzuki A, Fujikane T, Shimizu T, Sakai E. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology. 1992;49(6):431-5. [https://www.karger.com/Article/Abstract/227087 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1334539 PubMed]
# Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA, Greco FA. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992 Feb;10(2):282-91. [http://ascopubs.org/doi/10.1200/JCO.1992.10.2.282 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1310103 PubMed]
# Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, Johnson BE. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct;12(10):2022-34. [http://jco.ascopubs.org/content/12/10/2022.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7931470 PubMed]
# Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug;13(8):1871-9. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.8.1871 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7636529 PubMed]
# Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995 Oct;13(10):2594-9. [http://ascopubs.org/doi/full/10.1200/JCO.1995.13.10.2594 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7595712 PubMed]
# Pujol JL, Daur√®s JP, Rivi√®re A, Quoix E, Westeel V, Quantin X, Breton JL, Lemari√© E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst. 2001 Feb 21;93(4):300-8. [https://academic.oup.com/jnci/article/93/4/300/2906465 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11181777 PubMed]
# '''JCOG 9511:''' Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. [https://www.nejm.org/doi/full/10.1056/NEJMoa003034 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784874 PubMed]
# Sundstr√∏m S, Bremnes RM, Kaasa S, Aaseb√∏ U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72. [http://jco.ascopubs.org/content/20/24/4665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488411 PubMed]
# Artal-Cort√©s A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Meana A, Lomas M, Vadell C, Arrivi A, Alonso C, Maestu I, Campbell J, Rosell R. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer. 2004 Nov;6(3):175-83. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)70217-0/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15555219 PubMed]
# '''CALGB 9732:''' Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 1;23(16):3752-9. [http://ascopubs.org/doi/full/10.1200/JCO.2005.09.071 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15923572 PubMed]
# Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Clin Lung Cancer. 2005 Nov;7(3):183-9. [https://www.clinical-lung-cancer.com/article/S1525-7304(11)70409-0/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16354313 PubMed]
<!-- Presented in part (abstract and oral presentation) at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005, and at the 11th World Conference on Lung Cancer, Barcelona, Spain, July 3-6, 2005. -->
# Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. [http://jco.ascopubs.org/content/24/13/2038.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16648503 PubMed]
# Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2044-51. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.3332 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16648504 PubMed]
# '''JCOG 9702:''' Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007 Jul 16;97(2):162-9. Epub 2007 Jun 19. [https://www.nature.com/articles/6603810 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17579629 PubMed]
# Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, Faivre-Finn C, Blackhall F, Lorigan P. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer. 2008 Aug 5;99(3):442-7. [https://www.nature.com/articles/6604480 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527803/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18665190 PubMed]
# '''SWOG S0124:''' Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6. [http://ascopubs.org/doi/full/10.1200/JCO.2008.20.1061 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684855/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19349543 PubMed]
# Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010 Sep;21(9):1810-6. Epub 2010 Mar 15. [https://academic.oup.com/annonc/article/21/9/1810/145843 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20231298 PubMed]
# Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer Res. 2010 Jul;30(7):3031-8. [http://ar.iiarjournals.org/content/30/7/3031.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20683051 PubMed]
# '''SALUTE:''' Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21502556 PubMed]
# Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M; ‚ÄúAktion Bronchialkarzinom‚Äù (ABC Study Group). Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012 Sep;7(9):1432-9. [https://www.jto.org/article/S1556-0864(15)32944-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22895140 PubMed]
# '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed]
# Sun Y, Cheng Y, Hao X, Wang J, Hu C, Han B, Liu X, Zhang L, Wan H, Xia Z, Liu Y, Li W, Hou M, Zhang H, Xiu Q, Zhu Y, Feng J, Qin S, Luo X. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016 Apr 9;16:265. [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2301-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826513/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27061082 PubMed]
# '''COMBAT:''' Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. BMC Cancer. 2016 Aug 26;16:690. [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2741-z link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002146/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27566413 PubMed]
# '''CA184-156:''' Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016 Nov 1;34(31):3740-3748. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.6601 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27458307 PubMed]
# '''GOIRC-AIFA FARM6PMFJM:''' Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, Grossi F, Riccardi F, Ardizzoni A. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017 Apr 20;35(12):1281-1287. Epub 2017 Jan 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.4844 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28135143 PubMed]
# '''LUNGSTAR:''' Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017 May 10;35(14):1506-1514. Epub 2017 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.7391 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28240967 PubMed]

==Cisplatin, Etoposide, Bevacizumab {{#subobject:f451bd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3f85eb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 Spigel et al. 2011 (SALUTE)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy|Bevacizumab maintenance]]

===References===
# '''SALUTE:''' Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21502556 PubMed]

==Cisplatin & Irinotecan {{#subobject:277dbd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IP: '''<u>I</u>'''rinotecan, '''<u>P</u>'''latinol (Cisplatin)

===Variant #1, 30/65 {{#subobject:dc3fe1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/13/2038.long Hanna et al. 2006]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1 & 8

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] used according to 1999 American Society of Clinical Oncology guidelines
*"Erythropoietin was allowed at the discretion of the treating physician."

'''21-day cycle for 4 cycles; additional cycles could be given at physician discretion'''

===Variant #2, 60/60 {{#subobject:c0be38|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa003034 Noda et al. 2002 (JCOG 9511)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|EP]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684855/ Lara et al. 2009 (SWOG S0124)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|EP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.53.5153 Satouchi et al. 2014 (JCOG 0509)]
| style="background-color:#1a9851" |Phase III (C)
|Amrubicin & Cisplatin
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

====Supportive medications====
*"Hydration and administration of antiemetic drugs."

'''28-day cycle for 4 cycles'''

===Variant #3, 80/65 {{#subobject:dcf04b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/21/9/1810/145843 Zatloukal et al. 2010]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Etoposide_2|EP]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Irinotecan (Camptosar)]] 65 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 6 cycles'''

===References===
# '''JCOG 9511:''' Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. [https://www.nejm.org/doi/full/10.1056/NEJMoa003034 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11784874 PubMed]
<!-- Presented in part (abstract and oral presentation) at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005, and at the 11th World Conference on Lung Cancer, Barcelona, Spain, July 3-6, 2005. -->
# Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. [http://jco.ascopubs.org/content/24/13/2038.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16648503 PubMed]
# '''SWOG S0124:''' Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6. [http://ascopubs.org/doi/full/10.1200/JCO.2008.20.1061 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684855/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19349543 PubMed]
# Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010 Sep;21(9):1810-6. Epub 2010 Mar 15. [https://academic.oup.com/annonc/article/21/9/1810/145843 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20231298 PubMed]
<!-- Presented in part at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. -->
# '''JCOG 0509:''' Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.5153 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24638015 PubMed]

==Docetaxel monotherapy {{#subobject:46f6bb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:57c4cc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/10439170 Hesketh et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycles'''

===References===
# Hesketh PJ, Crowley JJ, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livingston RB, Gandara DR. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am. 1999 Jul-Aug;5(4):237-41. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10439170 PubMed]

==Ifosfamide monotherapy {{#subobject:d04316|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3276f5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract Ettinger et al. 2002 (ECOG E1588)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9851" |Less toxic
|-
|2. [[#Teniposide_monotherapy|Teniposide]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 5

====Supportive medications====
*[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> (route not specified) given three times per day on days 1 to 5; 0, 4, and 8 hours after each dose of ifosfamide

'''21-day cycle for 4 to 6 cycles''' 
====Subsequent treatment====
*Patients with CR: another 2 cycles of ifosfamide, then [[#Whole_brain_irradiation_2|prophylactic whole-brain irradiation]] if still in CR
*Patients with PR: ifosfamide until progression of disease, then [[#Cisplatin_.26_Etoposide_3|salvage EP]]

===References===
# '''ECOG E1588:''' Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer. 2002 Sep;37(3):311-8. [http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12234701 PubMed]

==Teniposide monotherapy {{#subobject:60479c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:964e45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 20%" |Study
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 20%" |Comparator
! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract Ettinger et al. 2002 (ECOG E1588)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9851" |Less toxic
|-
|2. [[#Ifosfamide_monotherapy|Ifosfamide]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Teniposide (Vumon)]] 60 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''21-day cycle for 4 to 6 cycles''' 
====Subsequent treatment====
*Patients with CR received another 2 cycles of teniposide. Patients with PR received teniposide until progression of disease, upon which they then received [[#Cisplatin_.26_Etoposide_3|salvage EP therapy]]. Patients with complete response after 6 to 8 cycles of teniposide received prophylactic whole-brain irradiation:

====Prophylactic whole-brain irradiation====
''Radiation starts 1 week after completion of induction chemotherapy.''
*[[External beam radiotherapy]], 2.5 Gy fractions x 10 fractions (total dose: 25 Gy)

===References===
# Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer. 2002 Sep;37(3):311-8. [http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12234701 PubMed]

=Extensive stage, consolidation after first-line therapy=
==Whole brain irradiation {{#subobject:37efe7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCI: '''<u>P</u>'''rophylactic '''<u>C</u>'''ranial '''<u>I</u>'''rradiation
===Regimen {{#subobject:b0bc9a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract Ettinger et al. 2002 (ECOG E1588)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa071780 Slotman et al. 2007 (EORTC 22993)]
| style="background-color:#1a9851" |Phase III (E)
|Observation
| style="background-color:#1a9850" |Superior OS
|-
|}
====Preceding treatment====
*ECOG E1588: [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]] versus [[#Ifosfamide_monotherapy|Ifosfamide]] versus [[#Teniposide_monotherapy|Teniposide]]
*EORTC 22993: Chemotherapy x 4 to 6 cycles (regimen not specified)
====Radiotherapy====
*[[External beam radiotherapy|Whole brain irradiation]] by one of the following: 20 Gy in 5 or 8 fractions, 24 Gy in 12 fractions, 25 Gy in 10 fractions, or 30 Gy in 10 or 12 fractions

'''One course'''
===References===
# '''Meta-analysis:''' Aup√©rin A, Arriagada R, Pignon JP, Le P√©choux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999 Aug 12;341(7):476-84. [https://www.nejm.org/doi/10.1056/NEJM199908123410703 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10441603 PubMed]
# '''ECOG E1588:''' Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer. 2002 Sep;37(3):311-8. [http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12234701 PubMed]
# '''EORTC 22993:''' Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007 Aug 16;357(7):664-72. [https://www.nejm.org/doi/full/10.1056/NEJMoa071780 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17699816 PubMed]

=Extensive stage, maintenance after first-line therapy=

==Atezolizumab monotherapy {{#subobject:3896a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f2a87b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 Horn et al. 2018 (IMpower133)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#IMpower133|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#IMpower133|See link]]
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_Etoposide.2C_Atezolizumab|CE & Atezolizumab]] x 4
====Immunotherapy====
*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1

'''21-day cycles'''

===References===
# '''IMpower133:''' Horn L, Mansfield AS, Szczƒôsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Sep 25. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1809064 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30280641 PubMed]

==Bevacizumab monotherapy {{#subobject:e2a180|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:60322b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 Spigel et al. 2011 (SALUTE)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_Etoposide.2C_Bevacizumab|Carboplatin, Etoposide, Bevacizumab induction]] x 4 or [[#Cisplatin.2C_Etoposide.2C_Bevacizumab|Cisplatin, Etoposide, Bevacizumab induction]] x 4
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.29.3423 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21502556 PubMed]

==Ipilimumab monotherapy {{#subobject:492277|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:be9690|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/24/1/75.long Reck et al. 2011]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Carboplatin.2C_Paclitaxel.2C_Ipilimumab|Carboplatin, Paclitaxel, Ipilimumab induction]]
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 10 mg/kg IV once on day 1

'''12-week cycles''' 

===References===
# Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. [http://annonc.oxfordjournals.org/content/24/1/75.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22858559 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.11.2321 Jett et al. 1994]
| style="background-color:#1a9851" |Phase III (C)
|IFN gamma
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(97)00174-3/pdf van Zandwijk et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|IFN gamma
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.8.2114 Schiller et al. 2001 (ECOG E7593)]
| style="background-color:#1a9851" |Phase III (C)
|Topotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/13/1/95/143629 Hanna et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|Etoposide
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ Ready et al. 2015 (CALGB 30504)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Sunitinib_monotherapy|Sunitinib monotherapy]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
''No further treatment.''
====Preceding treatment====
*ECOG E7593: [[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] x 4
*CALGB 30504: [[#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]] or [[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] for 4 to 6 cycles

===References===
# Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994 Nov;12(11):2321-6. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.11.2321 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7964947 PubMed]
# van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997 Oct;33(11):1759-66. [https://www.ejcancer.com/article/S0959-8049(97)00174-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9470829 PubMed]
# '''ECOG E7593:''' Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.8.2114 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11304763 PubMed]
# Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. [https://academic.oup.com/annonc/article/13/1/95/143629 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11863118 PubMed]
# '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.02.108 Shepherd et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|Marimastat
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further antineoplastic treatment.''
===References===
# Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002 Nov 15;20(22):4434-9. [http://ascopubs.org/doi/full/10.1200/JCO.2002.02.108 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12431965 PubMed]

==Sunitinib monotherapy {{#subobject:fa7428|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:957c3e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ Ready et al. 2015 (CALGB 30504)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Observation_2|Observation]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Preceding treatment====
*[[#Carboplatin_.26_Etoposide_2|Carboplatin & Etoposide]] or [[#Cisplatin_.26_Etoposide_2|Cisplatin & Etoposide]] for 4 to 6 cycles
====Chemotherapy====
*[[Sunitinib (Sutent)]] 150 mg PO once on day 1, then 37.5 mg PO once per day

'''Continued indefinitely'''

===References===
# '''CALGB 30504:''' Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.3105 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732163 PubMed]

=Relapsed or refractory disease=

==Amrubicin monotherapy {{#subobject:35370b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:514e41|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/35/4012.long von Pawel et al. 2014 (ACT-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Amrubicin (Calsed)]] 40 mg/m<sup>2</sup> IV over 5 minutes once per day on days 1 to 3

====Supportive medications====
*"Prophylactic antibiotics were recommended for patients at high risk of infectious complications."

'''21-day cycle for 6 cycles or until progression of disease''' 

''Patients who had at least stable disease by cycle 6 could receive another 6 cycles of treatment.'' 

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# '''ACT-1:''' von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosqu√©e L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Sch√ºtte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10. [http://jco.ascopubs.org/content/32/35/4012.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25385727 PubMed]

==Bendamustine monotherapy {{#subobject:6ed7fe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:35da2b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 33%" |Study
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 33%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990869/ Lammers et al. 2014]
| style="background-color:#91cf61" |Phase II
|33% (95% CI, 14-52%)
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycle for up to 6 cycles'''

===References===
# Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr;9(4):559-62. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990869/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24736081 PubMed]

==Best supportive care==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/34/5441.long O'Brien et al. 2006]
| style="background-color:#1a9851" |Phase III (C)
|[[#Topotecan_monotherapy|Oral topotecan]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}

''No active antineoplastic treatment.''

===References===
<!-- Presented in part at the International Association for the Study of Lung Cancer‚Äôs 11th World Conference on Lung Cancer, Barcelona, Spain, July 3-6, 2005. -->
# O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevi√° B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec 1;24(34):5441-7. [http://jco.ascopubs.org/content/24/34/5441.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17135646 PubMed]

==Cisplatin & Etoposide {{#subobject:eb644a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:159cb4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19900215)65:4%3C856::AID-CNCR2820650404%3E3.0.CO;2-6 O'Bryan et al. 1990 (SWOG S8215)]
| style="background-color:#1a9851" |Phase III (E)
|BTOC
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract Ettinger et al. 2002 (ECOG E1588)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*ECOG E1588: [[Small_cell_lung_cancer_-_historical#CAV_2|CAV]] versus [[#Ifosfamide_monotherapy|ifosfamide]] versus [[#Teniposide_monotherapy|teniposide]], with progression
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycles'''

===References===
# '''SWOG S8215:''' O'Bryan RM, Crowley JJ, Kim PN, Epstein RB, Neilan B, Coltman CA Jr, Stuckey WJ, Pazdur R. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer: a Southwest Oncology Group Study. Cancer. 1990 Feb 15;65(4):856-60. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19900215)65:4%3C856::AID-CNCR2820650404%3E3.0.CO;2-6 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2153435 PubMed]
# '''ECOG E1588:''' Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer. 2002 Sep;37(3):311-8. [http://www.lungcancerjournal.info/article/S0169-5002%2802%2900074-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12234701 PubMed]

==Cisplatin, Etoposide, Irinotecan {{#subobject:11d584|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e7a275|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30104-8/fulltext Goto et al. 2016 (JCOG0605)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Topotecan_monotherapy|Topotecan]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Irinotecan (Camptosar)]] 90 mg/m<sup>2</sup> IV once on day 8

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] SC once per day beginning on cycle 1 day 9, continued throughout except for days of chemotherapy

'''14-day cycle for 5 cycles'''

===References===
# '''JCOG0605:''' Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1147-57. Epub 2016 Jun 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30104-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27312053 PubMed]

==Docetaxel monotherapy {{#subobject:5918ce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a6b72f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.sciencedirect.com/science/article/pii/0959804994904553 Smyth et al. 1994]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycles'''

===References===
# Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB; The Early Clinical Trials Group of the EORTC. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer. 1994;30A(8):1058-60. [https://www.sciencedirect.com/science/article/pii/0959804994904553 link to SD article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7654428 PubMed]

==Etoposide monotherapy {{#subobject:4ae4d4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:4970d7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/2154857 Einhorn et al. 1990]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/8/10/1613.long Johnson et al. 1990]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day, taken every morning on an empty stomach

====Supportive medications====
*No routine antiemetics used.

'''21-day cycles'''

===References===
# Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol. 1990 Feb;17(1 Suppl 2):32-5. '''Not available online; abstract contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2154857 PubMed]
# Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990 Oct;8(10):1613-7. [http://jco.ascopubs.org/content/8/10/1613.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2170589 PubMed]

==Epirubicin & Ifosfamide {{#subobject:3661d7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EI: '''<u>E</u>'''pirubicin, '''<u>I</u>'''fosfamide

===Regimen {{#subobject:c74edb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.lungcancerjournal.info/article/S0169-5002%2811%2900386-2/abstract Jacot et al. 2012]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2

====Supportive medications====
*[[Mesna (Mesnex)]] (dose/route/schedule not specified) on days 1 & 2
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] use per physician discretion

'''28-day cycle for up to 6 cycles'''

===References===
# Jacot W, Pujol JL, Chakra M, Molinier O, Bozonnat MC, Gervais R, Quantin X. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. Lung Cancer. 2012 Feb;75(2):213-6. Epub 2011 Aug 9. [http://www.lungcancerjournal.info/article/S0169-5002%2811%2900386-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21831476 PubMed]

==Gemcitabine monotherapy {{#subobject:9a9c65|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5efd8c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/12/4/557.long van der Lee et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/21/8/1550.long Masters et al. 2003 (ECOG 1597)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
**Patients in Masters et al. 2003 with less than grade 2 toxicity with cycle 1 received 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15 of cycle 2 onwards

'''28-day cycle for up to 5 cycles (Lee et al. 2001) or indefinitely (ECOG 1597)'''

===References===
# van der Lee I, Smit EF, van Putten JW, Groen HJ, Schl√∂sser NJ, Postmus PE, Schramel FM. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 2001 Apr;12(4):557-61. [http://annonc.oxfordjournals.org/content/12/4/557.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11398892 PubMed]
# Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003 Apr 15;21(8):1550-5. [http://jco.ascopubs.org/content/21/8/1550.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12697880 PubMed]

==Ifosfamide monotherapy {{#subobject:a1f3a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d82a3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.sciencedirect.com/science/article/pii/0277537988902428 Cantwell et al. 1988]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Cantwell BM, Bozzino JM, Corris P, Harris AL. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol. 1988 Feb;24(2):123-9. [http://www.sciencedirect.com/science/article/pii/0277537988902428 link to SD article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2833398 PubMed]
# '''Review:''' Marangolo M, Giovanis P. Ifosfamide in small cell lung cancer. Oncology. 2003;65 Suppl 2:46-9. Review. [http://www.karger.com/Article/FullText/73358 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14586147 PubMed]

==Ifosfamide & Paclitaxel {{#subobject:6540a2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PI: '''<u>P</u>'''aclitaxel, '''<u>I</u>'''fosfamide

===Regimen {{#subobject:8e22a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.lungcancerjournal.info/article/S0169-5002%2807%2900325-X/abstract Park et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 2500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 & 2
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*[[Mesna (Mesnex)]] 500 mg/m<sup>2</sup> IV given three times per day on days 1 & 2: 15 minutes before, 4 hours after, and 8 hours after ifosfamide (total dose: 1500 mg/m<sup>2</sup>/day) 

'''21-day cycles'''

===References===
# Park S, Ahn MJ, Ahn JS, Lee J, Hong YS, Park BB, Lee SC, Hwang IG, Park JO, Lim H, Kang WK, Park K. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer. 2007 Oct;58(1):116-22. Epub 2007 Jul 12. [http://www.lungcancerjournal.info/article/S0169-5002%2807%2900325-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17624473 PubMed]

==Ipilimumab & Nivolumab {{#subobject:7bc416|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:aa43c1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract Antonia et al. 2016 (CheckMate 032)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Note: it is unclear which schedule of ipilimumab & nivolumab is preferred based on the abstract.''
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 1 mg/kg IV once on day 1
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Nivolumab_monotherapy_2|Nivolumab maintenance]]

===Variant #2 {{#subobject:b6a1ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract Antonia et al. 2016 (CheckMate 032)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Note: it is unclear which schedule of ipilimumab & nivolumab is preferred based on the abstract.''
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Nivolumab_monotherapy_2|Nivolumab maintenance]]

===References===
# '''CheckMate 032:''' Antonia SJ, L√≥pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, J√§ger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-95. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269741 PubMed]

==Irinotecan monotherapy {{#subobject:344d89|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c0a7e0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/10/8/1225.long Masuda et al. 1992]
| style="background-color:#ffffbe" |Phase II, <20 pts
|-
|}
====Chemotherapy====
*[[Irinotecan (Camptosar)]] 100 mg/m<sup>2</sup> IV over 90 minutes once per week

====Supportive medications====
*No routine prophylaxis against diarrhea, nausea, or vomiting used.

'''Continued indefinitely'''
===References===
# Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992 Aug;10(8):1225-9. [http://jco.ascopubs.org/content/10/8/1225.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1321891 PubMed]

==Nivolumab monotherapy {{#subobject:67a13c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5a9324|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract Antonia et al. 2016 (CheckMate 032)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1

'''14-day cycles'''

===References===
# Antonia SJ, L√≥pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, J√§ger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-95. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269741 PubMed]

==Paclitaxel monotherapy {{#subobject:e71ce6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, every 3 weeks {{#subobject:dbac57|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151229/ Smit et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO given twice, 12 and 6 hours prior to paclitaxel
*[[Clemastine (Tavist)]] 2 mg IV push once 30 minutes prior to paclitaxel 
*One of the following H2 blockers:
**[[Cimetidine (Tagamet)]] 300 mg IV push once 30 minutes prior to paclitaxel
**[[Ranitidine (Zantac)]] 50 mg IV push once 30 minutes prior to paclitaxel

'''21-day cycle for up to 5 cycles'''

===Variant #2, weekly paclitaxel {{#subobject:658a5f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ar.iiarjournals.org/content/26/1B/777.long Yamamoto et al. 2006]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV once 30 minutes prior to paclitaxel
*[[Ranitidine (Zantac)]] 50 mg IV once 30 minutes prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to paclitaxel
*If ANC less than 1000/uL or WBC count less than 2 x 10<sup>9</sup>/L, [[:Category:Granulocyte colony-stimulating factors|G-CSF]] 2 mcg/kg SC once per day is given until WBC count greater than or equal to 10 x 10<sup>9</sup>/L, except on days that paclitaxel is given

'''8-week cycles'''

===References===
# Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77(2):347-51. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151229/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/9461009 PubMed]
# Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006 Jan-Feb;26(1B):777-81. [http://ar.iiarjournals.org/content/26/1B/777.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16739353 PubMed]

==Temozolomide monotherapy {{#subobject:693cf4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:792fd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497567/ Zauderer et al. 2014]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Ondansetron (Zofran)]] 8 mg PO once 30 minutes prior to each dose

'''28-day cycles'''

===Variant #2 {{#subobject:96a285|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/18/4/1138.long Pietanza et al. 2012]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 21, with no food 2 hours before or 1 hour after temozolomide

====Supportive medications====
*[[Ondansetron (Zofran)]] 8 mg PO once prior to temozolomide prn nausea
*Patients with at least grade 3 lymphopenia received prophylaxis for Pneumocystis carinii pneumonia (no specific medication/dose/schedule listed)

'''28-day cycles'''

===References===
# Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012 Feb 15;18(4):1138-45. Epub 2012 Jan 6. [http://clincancerres.aacrjournals.org/content/18/4/1138.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22228633 PubMed]
# Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer. 2014 Nov;86(2):237-40. Epub 2014 Aug 17. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25194640 PubMed]

==Topotecan monotherapy {{#subobject:6e9625|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1.0 mg/m<sup>2</sup> {{#subobject:a060a6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30104-8/fulltext Goto et al. 2016 (JCOG0605)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin.2C_Etoposide.2C_Irinotecan|Cisplatin, Etoposide, Irinotecan]]
| style="background-color:#d73027" |Inferior OS
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.0 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

'''21-day cycle for 4 cycles'''

===Variant #2, 1.5 mg/m<sup>2</sup> {{#subobject:a08066|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/17/2/658.long von Pawel et al. 1999]
| style="background-color:#1a9851" |Phase III (E)
|[[Small_cell_lung_cancer_-_historical#CAV_3|CAV]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/25/15/2086.long Eckardt et al. 2007]
| style="background-color:#1a9851" |Phase III (C)
|Oral topotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/32/35/4012.long von Pawel et al. 2014 (ACT-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Amrubicin_monotherapy|Amrubicin]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

====Supportive medications====
*(varies depending on reference):
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] use per physician discretion
*In von Pawel et al. 2014 (ACT-1), "Prophylactic antibiotics were recommended for patients at high risk of infectious complications."

'''21-day cycles''' 

''Duration varies depending on reference:''
*In von Pawel et al. 1999 treatment is given until progression of disease, unacceptable toxicity, or 6 cycles beyond maximal response. Patients with stable disease after 4 cycles could have treatment discontinued at physician discretion. 
*In Eckardt et al. 2007, patients with complete or partial response continued treatment progression of disease or 2 cycles beyond best response. Patients with stable disease received at least 4 cycles therapy.
*In von Pawel et al. 2014 (ACT-1), treatment was given for 6 cycles or until progression of disease. Patients who had at least stable disease by cycle 6 could receive another 6 cycles of treatment.

===Variant #3, oral route {{#subobject:cb27be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/34/5441.long O'Brien et al. 2006]
| style="background-color:#1a9851" |Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/25/15/2086.long Eckardt et al. 2007]
| style="background-color:#1a9851" |Phase III (E)
|IV topotecan (1.5 mg/m<sup>2</sup>)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 2.3 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycles''' 

''Duration of treatment details vary depending on reference. In O'Brien et al. 2006, treatment is given for at least 4 cycles, though this depended on tolerability and response. In Eckardt et al. 2007, patients with complete or partial response continued treatment progression of disease or 2 cycles beyond best response. Patients with stable disease received at least 4 cycles of therapy.''

===References===
# von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999 Feb;17(2):658-67. [http://jco.ascopubs.org/content/17/2/658.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10080612 PubMed]
<!-- Presented in part at the International Association for the Study of Lung Cancer‚Äôs 11th World Conference on Lung Cancer, Barcelona, Spain, July 3-6, 2005. -->
# O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevi√° B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec 1;24(34):5441-7. [http://jco.ascopubs.org/content/24/34/5441.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17135646 PubMed]
<!-- Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 to June 3, 2003. -->
# Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007 May 20;25(15):2086-92. [http://jco.ascopubs.org/content/25/15/2086.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17513814 PubMed]
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011. -->
# '''ACT-1:''' von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosqu√©e L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Sch√ºtte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10. [http://jco.ascopubs.org/content/32/35/4012.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25385727 PubMed]
# '''JCOG0605:''' Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1147-57. Epub 2016 Jun 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30104-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27312053 PubMed]

==Vinorelbine monotherapy {{#subobject:4177e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 25 mg/m<sup>2</sup> {{#subobject:be1346|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.karger.com/Article/Abstract/227555 Furuse et al. 1996]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #2, 30 mg/m<sup>2</sup> {{#subobject:f20f90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ejcancer.com/article/0959-8049(93)90112-S/pdf Jassem et al. 1993]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===References===
# Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, Gozzelino F, Planting A, van Zandwijk N; EORTC Lung Cancer Cooperative Group. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer. 1993;29A(12):1720-2. [https://www.ejcancer.com/article/0959-8049(93)90112-S/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8398301 PubMed]
# Furuse K, Kubota K, Kawahara M, Takada M, Kimura I, Fujii M, Ohta M, Hasegawa K, Yoshida K, Nakajima S, Ogura T, Niitani H; Japan Lung Cancer Vinorelbine Study Group. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 1996 Mar-Apr;53(2):169-72. [https://www.karger.com/Article/Abstract/227555 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8604245 PubMed]

=Maintenance after salvage therapy=
==Nivolumab monotherapy {{#subobject:b2f564|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5c569f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 50%" |Study
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract Antonia et al. 2016 (CheckMate 032)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
====Preceding treatment====
*[[#Ipilimumab_.26_Nivolumab|Ipilimumab & Nivolumab]]
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1

'''14-day cycles'''

===References===
# '''CheckMate 032:''' Antonia SJ, L√≥pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, J√§ger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-95. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30098-5/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27269741 PubMed]

[[Category:Small cell lung cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Thoracic cancers]]
